Quellenangaben: Offener Brief an Herrn Vasella, CEO und Verwaltungsratspräsident von Novartis

1. Innovation Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products. U.S. Department of Health and Human Services. Food and Drug Administration (FDA), 2004, S.8

2. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997;3(12):1389-1393.

3. Diseases NI. Clinical Trials of HIV Vaccines: National Institutes of Health. U.S. Department of Health and Human Services, 2007.

4. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985;82(20):7096-7100.

5. Soudeyns H, Yao XI, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991;35(7):1386-1390.

6. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990;248(4953):358-361.

7. Hartung T. Toxicology for the twenty-first century. Nature. 2009 Jul 9;460(7252):208-12.